TL;DR: Aetna modified CPB 0711 governing mecasermin (Increlex) coverage, with an effective date of September 26, 2025. The updated policy document is currently returning a 404 error. Here's what billing teams need to do before claims start hitting the wall.
Aetna updated its mecasermin (Increlex) coverage policy under CPB 0711 on September 26, 2025. Mecasermin is a recombinant human insulin-like growth factor-1 (IGF-1) used to treat severe primary IGF-1 deficiency and growth failure in children. The policy data available at the time of this post returned a 404 error from Aetna's public-facing clinical policy bulletin page, which means no policy content can be confirmed. We'll cover what that means for your billing team — and what to do about it.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Mecasermin (Increlex) — CPB 0711 |
| Policy Code | CPB 0711 |
| Change Type | Modified |
| Effective Date | 2025-09-26 |
| Impact Level | High (pending full policy text confirmation) |
| Specialties Affected | Pediatric endocrinology, pediatrics, rare disease clinics |
| Key Action | Pull the current CPB 0711 document directly from Aetna's provider portal and audit any pending mecasermin claims before submitting |
Aetna Mecasermin Coverage Policy: What We Know and What We Don't in 2025
Aetna's mecasermin coverage policy under CPB 0711 was flagged as modified on September 26, 2025. That's a real change event logged in the payer's policy update system. The policy governs reimbursement for mecasermin (brand name Increlex), a specialty biologic that treats severe primary IGF-1 deficiency and growth failure in pediatric patients.
The problem: Aetna's public clinical policy bulletin URL for CPB 0711 is returning a 404 error as of this writing. The page is either temporarily down or the updated document hasn't been published to the public portal yet. That's a risk for your billing team, not a technicality.
If you're billing mecasermin and your team is relying on any version of this policy that predates September 26, you're flying blind. You need the updated document before you submit claims or prior authorization requests against this policy.
Aetna Mecasermin (Increlex) Coverage Criteria and Medical Necessity Requirements 2025
Because the CPB 0711 policy document is returning a 404 error, no coverage criteria can be confirmed from this policy update. The medical necessity thresholds, IGF-1 requirements, growth velocity standards, and any other clinical criteria Aetna now applies to mecasermin claims are not available from the source data.
Do not rely on cached policy documents, third-party summaries, or prior versions of CPB 0711 to make billing decisions. The criteria your team uses for prior authorization and medical necessity documentation must come from the current updated policy text — and that document isn't publicly accessible yet.
Once the updated CPB 0711 is posted, retrieve it directly from Aetna's provider portal. If you can't access it within five business days of the September 26, 2025, effective date, call Aetna provider relations and request the updated policy document in writing. Document that call.
If you're uncertain how this policy change applies to your current mecasermin patients, talk to your compliance officer before submitting any claims against CPB 0711 after September 26, 2025.
Aetna Mecasermin Exclusions and Non-Covered Indications
The updated CPB 0711 document is not accessible due to the 404 error described above. No exclusions or non-covered indications can be confirmed from the available source data.
Do not assume the prior exclusion framework still applies. Retrieve the updated policy text and map every exclusion criterion to your current patient population before submitting claims.
Coverage Status: Cannot Be Confirmed
Because the updated CPB 0711 document is not publicly accessible as of this post, no coverage determinations can be confirmed. Any table of covered or non-covered indications would be speculative.
Once the updated policy document is posted, your billing team should document every coverage determination and map it to your current mecasermin patients before submitting claims or prior authorization requests.
Prior Authorization Requirements
Whether prior authorization is required for mecasermin under the updated CPB 0711 is not confirmed by the source data. Verify PA requirements directly with Aetna before submitting any mecasermin claims after September 26, 2025.
Call Aetna provider relations if the portal isn't yet showing the updated policy. Get the PA requirement confirmed in writing.
Aetna Mecasermin Billing Guidelines and Action Items 2025
Here's what your billing team should do right now.
| # | Action Item |
|---|---|
| 1 | Pull the current CPB 0711 document directly from Aetna's provider portal. Don't use a cached PDF or third-party summary. Search CPB 0711 on Aetna's provider portal. If it's still returning a 404, call Aetna provider relations and request the updated policy document in writing. Document that call. |
| 2 | Audit all pending mecasermin prior authorization requests. Any PA submitted before September 26, 2025, that hasn't been approved yet may be reviewed against the new criteria. Check the status of every open mecasermin PA in your queue today. |
| 3 | Review existing approved PAs for active patients. If a patient already has an approved PA for mecasermin, confirm whether that authorization pre-dates the September 26 change. Aetna can — and sometimes does — apply new criteria at the point of reauthorization. Know your reauth dates. |
| 4 | Update your medical necessity documentation templates. Once you have the updated policy text, flag every criteria item and map it to your documentation workflow. Don't update templates based on assumptions about what changed — wait for the actual document. |
| 5 | Brief your pediatric endocrinology partners. The medical necessity criteria for mecasermin billing live in the clinical notes. Once you have the updated CPB 0711, share the relevant documentation requirements with your endocrinologists. If their notes don't mirror the current criteria, the PA will get denied regardless of whether the patient qualifies clinically. |
| 6 | Set a claim denial alert for mecasermin claims in your billing system. If denials start appearing for mecasermin after September 26, 2025, you want to know immediately — not at month-end. Watch for any uptick in medical necessity denials on mecasermin claims and investigate them against the updated policy criteria. |
| 7 | If you can't get the updated policy text within five business days, escalate. Your payer relations team or a billing consultant with direct Aetna contacts can often get updated policy documents before they're posted publicly. Don't wait for the portal to catch up. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Mecasermin Under CPB 0711
The CPB 0711 policy document returned a 404 error. No codes are available from this policy update.
Do not bill mecasermin claims based on codes from prior policy versions, third-party summaries, or any source other than the updated CPB 0711 document. Retrieve the current policy text directly from Aetna's provider portal and confirm all relevant HCPCS, CPT, and ICD-10 codes before submitting claims.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.